These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 9663484)
1. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484 [TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819 [TBL] [Abstract][Full Text] [Related]
3. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. Kim HR; Park MK; Cho ML; Yoon CH; Lee SH; Park SH; Leng L; Bucala R; Kang I; Choe J; Kim HY J Rheumatol; 2007 May; 34(5):927-36. PubMed ID: 17407222 [TBL] [Abstract][Full Text] [Related]
4. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. Jackson JR; Minton JA; Ho ML; Wei N; Winkler JD J Rheumatol; 1997 Jul; 24(7):1253-9. PubMed ID: 9228120 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Cho ML; Jung YO; Moon YM; Min SY; Yoon CH; Lee SH; Park SH; Cho CS; Jue DM; Kim HY Immunol Lett; 2006 Mar; 103(2):159-66. PubMed ID: 16368150 [TBL] [Abstract][Full Text] [Related]
7. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Olszewski WL; Pazdur J; Kubasiewicz E; Zaleska M; Cooke CJ; Miller NE Arthritis Rheum; 2001 Mar; 44(3):541-9. PubMed ID: 11263768 [TBL] [Abstract][Full Text] [Related]
8. Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytes. Cinelli M; Guiducci S; Del Rosso A; Pignone A; Del Rosso M; Fibbi G; Serratì S; Gabrielli A; Giacomelli R; Piccardi N; Matucci Cerinic M Scand J Rheumatol; 2006; 35(5):346-50. PubMed ID: 17062432 [TBL] [Abstract][Full Text] [Related]
9. Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis. Pufe T; Bartscher M; Petersen W; Tillmann B; Mentlein R Arthritis Rheum; 2003 Mar; 48(3):660-7. PubMed ID: 12632418 [TBL] [Abstract][Full Text] [Related]
10. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Ballara S; Taylor PC; Reusch P; Marmé D; Feldmann M; Maini RN; Paleolog EM Arthritis Rheum; 2001 Sep; 44(9):2055-64. PubMed ID: 11592367 [TBL] [Abstract][Full Text] [Related]
11. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. Nagashima M; Asano G; Yoshino S J Rheumatol; 2000 Oct; 27(10):2339-42. PubMed ID: 11036826 [TBL] [Abstract][Full Text] [Related]
13. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Iwahashi M; Yamamura M; Aita T; Okamoto A; Ueno A; Ogawa N; Akashi S; Miyake K; Godowski PJ; Makino H Arthritis Rheum; 2004 May; 50(5):1457-67. PubMed ID: 15146415 [TBL] [Abstract][Full Text] [Related]
14. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Chabaud M; Miossec P Arthritis Rheum; 2001 Jun; 44(6):1293-303. PubMed ID: 11407688 [TBL] [Abstract][Full Text] [Related]
15. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Jain A; Nanchahal J; Troeberg L; Green P; Brennan F Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425 [TBL] [Abstract][Full Text] [Related]
16. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841 [TBL] [Abstract][Full Text] [Related]
17. The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane. Hosaka K; Ryu J; Saitoh S; Ishii T; Kuroda K; Shimizu K Cytokine; 2005 Dec; 32(6):263-9. PubMed ID: 16406555 [TBL] [Abstract][Full Text] [Related]
18. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Butler DM; Maini RN; Feldmann M; Brennan FM Eur Cytokine Netw; 1995; 6(4):225-30. PubMed ID: 8789287 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Dai SM; Matsuno H; Nakamura H; Nishioka K; Yudoh K Arthritis Rheum; 2004 Feb; 50(2):432-43. PubMed ID: 14872485 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Redlich K; Kiener HP; Schett G; Tohidast-Akrad M; Selzer E; Radda I; Stummvoll GH; Steiner CW; Gröger M; Bitzan P; Zenz P; Smolen JS; Steiner G Arthritis Rheum; 2001 Feb; 44(2):266-74. PubMed ID: 11229456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]